Accolade (NASDAQ:ACCD) Stock, Quote.Headers.trade-ideas

Accolade

Accolade Inc offers technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. The company's platform combines open, cloud-based intelligent technology with multimodal support from a team of Accolade Care Advocates and clinicians, including registered nurses, physician medical directors, pharmacists, primary care physicians, and other professionals to provide advocacy, medical opinion, and virtual primary care services.

Chengdu,,China,-,Mar,10,,2020:,Apple,Store,In,Downtown

News

Price Target

Markets

Analyst Ratings

Trading Ideas

AAPL

ACCD

BWIN

CHWY

RIVN

Apple To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Friday

Nike Photo by pixfly on Shutterstock

Pre-Market Outlook

Movers

APLS

KRUS

PSNY

PTCT

RCKT

Nike, Accolade And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

stock chart-1863880_1920-60

Earnings

Guidance

After-Hours Center

Accolade Inc shares are tanking in Thursday&#39;s after-hours session after the company reported financial results for its fiscal first quarter and issued weak guidance.

Accolade Stock Tumbles On Q1 Earnings, Weak Guidance: What You Need To Know

Accolade Inc

Jefferies analyst Julien Dumoulin-Smith initiates coverage on WEC Energy Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>) with a Hold rating and announces Price Target of $102.

Initiation

Jefferies Initiates Coverage On WEC Energy Group with Hold Rating, Announces Price Target of $102

The head-to-head matchup between former President Donald Trump and Vice President Kamala Harris could come down to how several swing states fall in the<a href="https://www.benzinga.com/topic/2024-election"> 2024 presidential election.</a>
A new poll shows which candidate is making up ground in the key seven states.
What Happened: Harris has been trending up <a href="https://www.benzinga.com/general/politics/24/09/40910999/trump-in-trouble-vice-president-harris-has-record-6-point-lead-in-2024-election-poll-after-debat">in 2024 election polls</a> of nationally registered voters, posting her largest lead in the weekly Morning Consult poll this week in the head-to-head matchup.
A new poll of <a href="https://www.benzinga.com/topic/swing-states">swing state</a> voters, which covers seven key battleground states, could show a different picture.
Here are the results from the September Emerson College swing state <a href="https://emersoncollegepolling.com/september-2024-swing-state-polls-trump-and-harris-locked-in-tight-presidential-race/">polls </a>with the results from August in parentheses:
<ul>
<li>Arizona: Trump 49% (50%), Harris 48% (47%)</li>
<li>Georgia: Trump 50% (48%), Harris 47% (49%)</li>
<li>Michigan: Harris 49% (50%), Trump 47% (47%)</li>
<li>Nevada: Trump 48% (48%), Harris 48% (49%)</li>
<li>North Carolina: Harris 49% (48%), Trump 48% (49%)</li>
<li>Pennsylvania: Trump 48% (48%), Harris 47% (48%)</li>
<li>Wisconsin: Trump 49% (49%), Harris 48% (48%)</li>
</ul>
The results show that Trump leads Harris in four of the seven states and is tied with the vice president in one state. Harris leads Trump in two states. Each candidate led three states in the August poll.
Trump gained support in one state and lost support in two states, with four states remaining the same from August. Harris gained support in two states and lost support in four states.
"There has been marginal movement in the presidential election since the late August Emerson swing state polls before the presidential debate," Emerson College Polling executive director Spencer Kimball said. 
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent091924">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: The seven swing states in question together represent 93 electoral votes in the 2024 election. Six of the seven states above were won by Biden in the 2020 election with Trump winning North Carolina. Several of the states were flipped from Trump's win in the 2016 election.
A Marist poll recently found how swing state voters in Michigan, Pennsylvania and Wisconsin would vote in the 2024 election if it were held today. The race for Pennsylvania and Wisconsin was close with Trump and Harris tied in Pennsylvania and Harris leading by one point in Wisconsin.
In the state of Michigan, Harris had a five-point lead over Trump.
The three states together represent 44 electoral votes and could prove important in the 2024 election. Trump was the first Republican presidential candidate to sweep the three states since Ronald Reagan in 1984, <a href="https://nypost.com/2024/09/19/us-news/trump-harris-neck-and-neck-among-likely-voters-in-pennsylvania-and-wisconsin-veep-up-5-in-michigan-polls/">according </a>to the New York Post. Biden won all three of the states in the 2020 election.
All seven swing states see voters pick the economy as the top issue ahead of the election. Immigration, threats to democracy and housing affordability are also top voter issues in swing states.
With less than two months until the 2024 election, the race between Harris and Trump remains close and swing states continue to be one of the most monitored polling items given their importance.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent091924">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Photo: Shutterstock

Politics

Harris In Trouble? New Swing State Poll Shows Trump Gains Ground In Key Battleground Areas For 2024 Election

Jefferies analyst Paul Zimbardo initiates coverage on Xcel Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XEL#NASDAQ">XEL</a>) with a Hold rating and announces Price Target of $70.

Jefferies Initiates Coverage On Xcel Energy with Hold Rating, Announces Price Target of $70

Jefferies analyst Julien Dumoulin-Smith initiates coverage on Alliant Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNT#NASDAQ">LNT</a>) with a Hold rating and announces Price Target of $67.

Jefferies Initiates Coverage On Alliant Energy with Hold Rating, Announces Price Target of $67

Jefferies analyst Julien Dumoulin-Smith initiates coverage on OGE Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGE#NYSE">OGE</a>) with a Buy rating and announces Price Target of $46.

Jefferies Initiates Coverage On OGE Energy with Buy Rating, Announces Price Target of $46

Jefferies analyst Julien Dumoulin-Smith initiates coverage on Ameren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>) with a Buy rating and announces Price Target of $97.

Jefferies Initiates Coverage On Ameren with Buy Rating, Announces Price Target of $97

Jefferies analyst Julien Dumoulin-Smith initiates coverage on Evergy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVRG#NASDAQ">EVRG</a>) with a Buy rating and announces Price Target of $70.

EVRG

Jefferies Initiates Coverage On Evergy with Buy Rating, Announces Price Target of $70

Jefferies analyst Julien Dumoulin-Smith initiates coverage on Pinnacle West Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNW#NYSE">PNW</a>) with a Buy rating and announces Price Target of $104.

Jefferies Initiates Coverage On Pinnacle West Capital with Buy Rating, Announces Price Target of $104

Jefferies analyst Julien Dumoulin-Smith initiates coverage on Exelon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>) with a Buy rating and announces Price Target of $46.

Jefferies Initiates Coverage On Exelon with Buy Rating, Announces Price Target of $46

Jefferies analyst Paul Zimbardo initiates coverage on PPL (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPL#NYSE">PPL</a>) with a Buy rating and announces Price Target of $38.

Jefferies Initiates Coverage On PPL with Buy Rating, Announces Price Target of $38

Mortgage rates continue to <a href="https://www.benzinga.com/news/24/09/40921345/mortgage-rates-drop-to-2-year-low-refinancing-hits-fastest-pace-since-2022-rocket-lendingtree-among">fall toward 6%</a> as the housing market absorbs the Federal Reserve&#8217;s 0.5% rate cut on Wednesday, raising demand for refinancing and buying, stated Freddie Mac.
The average rate for a 30-year fixed mortgage fell to 6.09% on Thursday, down from 6.2% a week ago and 7.19% a year earlier, according to Freddie Mac&#8217;s Primary Market Mortgage Survey.
The rate for a 15-year fixed mortgage declined to 5.15%, down from 5.27% a week ago and 6.54% a year earlier.
"Mortgage rates continued declining towards the six percent mark, reviving purchase and refinance demand for many consumers," said Sam Khater, Freddie Mac's chief economist.
Read Also:<a href="https://www.benzinga.com/top-stories/24/09/40923657/single-family-housing-starts-are-up-as-mortgage-rates-decline-fed-eyes-lower-rates"> Single-Family Housing Starts Are Up As Mortgage Rates Decline, Fed Eyes Lower Rates</a>
"While mortgage rates do not directly follow moves by the Federal Reserve, this first cut in over four years will have an impact on the housing market. Declining mortgage rates over the last several weeks indicate this cut was mostly baked in, but we expect rates to fall further, sparking more housing activity."
Exchange-traded funds that hold mortgage stocks are sensitive to mortgage rates because they primarily invest in mortgage-backed securities (MBS) or mortgage-related assets, which are directly impacted by changes in interest rates.
<ul>
<li>IShares Mortgage Real Estate ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/REM#BATS">REM</a>) rose 0.82%</li>
<li>VanEck Mortgage REIT Income ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MORT#NYSE">MORT</a>) went up 0.74%</li>
<li>IShares MBS ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBB#NASDAQ">MBB</a>) ticked up 0.06%</li>
</ul>
IShares Mortgage Real Estate ETF holds 15.2% of the REIT, Annaly Capital Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NLY#NYSE">NLY</a>), while VanEck Mortgage REIT Income ETF holds 11.1%.
Read Now:
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40817001/mortgage-rates-fall-to-lowest-level-since-february-2023">Mortgage Rates Fall To Lowest Level Since February 2023</a></li>
</ul>
Photo: Shutterstock

REIT

ETFs

Real Estate

FMCC

MORT

iShares FTSE NAREIT Mortgage PLUS Capped Index Fund

Mortgage Rates Near 6%, Demand Increases For Refinancing, Purchases

Jefferies analyst Julien Dumoulin-Smith initiates coverage on Duke Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) with a Buy rating and announces Price Target of $138.

Jefferies Initiates Coverage On Duke Energy with Buy Rating, Announces Price Target of $138

Morgan Stanley analyst Jeffrey Hung upgrades Centessa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTA#NASDAQ">CNTA</a>) from Equal-Weight to Overweight and raises the price target from $11 to $26.

Upgrades

CNTA

Morgan Stanley Upgrades Centessa Pharmaceuticals to Overweight, Raises Price Target to $26

South Korean gaming giant Krafton's recent acquisition of Microsoft Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) Tango Gameworks, known for titles like The Evil Within and Hi-Fi Rush, marked a significant move in the <a href="https://www.benzinga.com/general/gaming">gaming sector.</a>
The deal, announced on Aug. 13, was driven more by a commitment to preserving creative talent than by financial incentives.
See Also: <a href="https://www.benzinga.com/general/gaming/24/08/40320631/krafton-saves-tango-gameworks-acquires-hi-fi-rush-ip-from-xbox">Krafton Saves Tango Gameworks: Acquires Hi-Fi Rush IP From Xbox</a>
<h1 class="wp-block-heading">Commitment Over Profit</h1>
&#8220;We don't think Hi-Fi Rush 2 is going to make us money, to be frank,&#8221; CEO Changhan Kim revealed in <a href="https://www.gamedeveloper.com/business/-we-don-t-think-hi-fi-rush-2-is-going-to-make-us-money-krafton-ceo-says-tango-gameworks-acquisition-is-about-legacy">dialogue </a>with Game Developer. 
&#8220;We wanted to maintain their legacy,&#8221; he added. &#8220;Although they did not have a big success in their games, we saw many creatives worth pursuing. That&#8217;s why we wanted to work with that organization.&#8221;
<h1 class="wp-block-heading">Strategic Focus On Hi-Fi Rush</h1>
The acquisition focused specifically on the Hi-Fi Rush intellectual property. 
&#8220;Because Hi-Fi Rush fans really want to see sequels, we negotiated with Tango Gameworks' parent company to acquire that IP as well,&#8221; Kim explained. 
This move was intended to streamline the acquisition process and ensure the game's legacy continued without unnecessary delays.
Kim also addressed the practical aspects of the deal. "If we were to acquire all IPs, I think it's going to complicate the deal too much," he noted. 
<h1 class="wp-block-heading">Staff Transition, Future Plans</h1>
The acquisition involved around 50 of Tango Gameworks&#8217; 100 employees, with the remaining staff not joining Krafton. 
Kim reassured that Krafton had no plans to reduce the new studio's staff and hinted at potential expansion.
&#8220;Krafton is a pretty big company, but Microsoft is very complicated,&#8221; Kim said. &#8220;We wanted to help the team continue developing their games, but especially Hi-Fi Rush.&#8221;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/05/38791690/xbox-exec-sarah-bond-addresses-microsofts-studio-closures-its-always-extraordinarily-hard-to-make-">Xbox Exec Sarah Bond Addresses Microsoft&#8217;s Studio Closures: &#8216;It&#8217;s Always Extraordinarily Hard To Make Decisions Like That&#8217;</a></li>
</ul>
Photo: Courtesy of Tango Gameworks.

Gaming

General

MSFT

Why Krafton Bought Tango Gameworks From Microsoft: CEO Kim Reveals 'We Don't Think Hi-Fi Rush 2 Is Going To Make Us Money'

Politan Capital Management (together with its affiliates, "Politan"), a 9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>), today commented on the outcome of the Company's Annual Meeting of Stockholders (the "Annual Meeting").
Both of Politan's independent nominees – Darlene Solomon and William Jellison – were elected to the Board.1 Politan greatly appreciates the support and engagement from its fellow Masimo shareholders during this process.
Darlene Solomon, William Jellison, Michelle Brennan and Quentin Koffey issued the following joint statement:
"While each of us is independent and brings our own unique perspectives, we are united in our enthusiasm for Masimo's future as a leading, innovation-focused growth company. We look forward to meeting with, learning from, and working together with the Healthcare and Consumer employees to make Masimo an even greater company. We would also like customers to know that we will be completely focused on preventing any disruption to their service and support. We will have more to share soon."

Management

MASI

Politan Comments On Results Of Masimo's 2024 Annual Meeting, Both Of Politan's Independent Nominees Darlene Solomon And William Jellison Were Elected To The Board

- Initiation of pivotal CYB003 Phase 3 study in Major Depressive Disorder ("MDD") expected imminently -
- 12-month efficacy data from Phase 2 study of CYB003 in MDD expected in early Q4 2024 -
- Phase 2 topline efficacy and safety results for CYB004 in Generalized Anxiety Disorder ("GAD") expected year-end 2024 or early Q1 2025 -
- Strengthened R&amp;D team with addition of experienced drug development leaders Dr. Atul R. Mahableshwarkar, and Dr. Tom Macek, as program leads for CYB003 and CYB004, respectively -
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cybin.com%2F&amp;esheet=54124810&amp;newsitemid=20240919771162&amp;lan=en-US&amp;anchor=Cybin+Inc.&amp;index=1&amp;md5=66087b8f12a3993545dbd3142c3afc66">Cybin Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYBN#NYSE">CYBN</a>) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported recent clinical accomplishments and key upcoming clinical milestones.

Biotech

CYBN

Cybin Provides Corporate Update On Upcoming Clinical Milestones; Initiation Of Pivotal CYB003 Phase 3 Study In Major Depressive Disorder Expected Imminently; 12-Month Efficacy Data From Phase 2 Study Of CYB003 In MDD Expected In Early Q4 2024; Phase 2 Topline Efficacy And Safety Results For CYB004 In Generalized Anxiety Disorder Expected Year-End 2024 Or Early Q1 2025

ASTC

Astrotech FY24 EPS $(7.12) Down From $(5.95) YoY; Revenue $1.66M Up From $750K YoY

Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) shares<a href="https://www.benzinga.com/news/24/09/40897994/whats-going-on-with-intel-stock-on-tuesday"> skyrocketed on Thursday</a> after Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) assured investors it would not drop its majority stake in the Israeli autonomous driving company.
Mobileye gained 14.99% to close at $13.35 on Thursday, marking its largest intraday jump since late October 2022.
&#8220;We currently do not have any plans to divest a majority interest in the company,&#8221; Intel said in a statement.
&#8220;By providing Mobileye with separation and autonomy, we have enhanced its ability to capitalize on growth opportunities and accelerate its path to creating even greater value.&#8221;
Read Also: <a href="https://www.benzinga.com/news/24/09/40941075/whats-going-on-with-autonomous-driving-stock-mobileye-thursday">What&#8217;s Going On With Autonomous Driving Stock Mobileye Thursday?</a>
Intel, which holds an 88% stake in Mobileye, said it believes in the future of autonomous driving technology and in Mobileye's &#8220;unique role as a leader&#8221; in developing advanced driver assistance systems.
Intel CEO Pat Gelsinger has been changing his company's operations and showed more of his plans earlier this week to get the troubled chipmaker back on track, including pausing building factories in Germany and Poland and turning its manufacturing sector into a wholly owned subsidiary, Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-09-19/mobileye-jumps-after-intel-says-it-won-t-divest-majority-stake?srnd=homepage-americas&amp;sref=TBDibEcD">reported</a>.
Intel discussed possibly selling some its Mobileye stake either on the public market or through a third-party sale, Bloomberg reported earlier this month.
Mobileye, which provides both software and hardware for self-driving systems, was acquired by Intel in 2017 for about $15 billion. It had an initial public offering in 2022, but Intel held most of the stake.
Read Now:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/10/35469115/mobileye-lowered-revenue-outlook-but-these-analysts-are-still-bullish-heres-why">Mobileye Lowered Revenue Outlook But These Analysts Are Still Bullish &#8211; Here&#8217;s Why</a></li>
</ul>
Photo: Ilan Ben Oudiz<a href="https://creativecommons.org/licenses/by-sa/4.0"> via </a>Wikimedia Commons

Equities

Global

Tech

INTC

MBLY

Mobileye Soars After Intel Says It Will Not Sell Majority Stake

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4259289-1&amp;h=1854567284&amp;u=https%3A%2F%2Fnauticusrobotics.com%2F&amp;a=Nauticus+Robotics+Inc.">Nauticus Robotics Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) a leading innovator in autonomous subsea robotics and software, today announced receipt of a letter from the Nasdaq Stock Market LLC ("Nasdaq") approving an extension of time to regain compliance with all listing standards.
The letter received from Nasdaq grants Nauticus an exception until December 31, 2024 to demonstrate compliance with the Nasdaq Capital Market listing rules. Nauticus management presented its detailed plan to gain compliance during the Nasdaq Hearings Panel meeting held on September 5, 2024.
Nauticus will continue to work through its plan with intent to resolve all compliance issues before the deadline of December 31, 2024.
With the granting of this Nasdaq exception, Nauticus remains listed on the Nasdaq capital market. Once the compliance plan is fully executed, Nauticus will make further disclosures describing the actions taken by the Company to achieve compliance.&nbsp;

KITT

Nauticus Robotics Announces Notification Of NASDAQ Listing Extension, Will Continue To Work Through Its Plan With Intent To Resolve All Compliance Issues Before The Deadline Of December 31, 2024

WIIM

AGBA

AGBA Group shares are trading higher after the company announced all AGBA/Triller merger closing conditions have been met, with the exception of the final Nasdaq listing regulatory approval.

Biggest stock movers today: PLUG, NKE, DJT, and more

In a report released today, Allen Lutz from Bank of America Securities maintained a Buy rating on Accolade (ACCD – Research Report). The company's ...

Bank of America Securities Sticks to Its Buy Rating for Accolade (ACCD)

Analysts fell to the sidelines weighing in on Accolade (ACCD – Research Report), Envista Holdings (NVST – Research Report) and Edwards Lifesciences...

Analysts' Top Healthcare Picks: Accolade (ACCD), Envista Holdings (NVST)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Myomo (MYO – Research Report) and Accolade (ACCD – R...

Analysts Offer Insights on Healthcare Companies: Myomo (MYO) and Accolade (ACCD)

Catalyst Watch: Disney earnings, Costco sales update, MicroStrategy split, and eyes on AI patents

Accolade gains on report of takeover interest

In a report released yesterday, Michael Cherny from Leerink Partners reiterated a Buy rating on Accolade (ACCD – Research Report), with a price tar...

Accolade's Growth and Profitability Outlook Underscored by Buy Rating

Accolade: Consider Both Short-Term Revenue Outlook And Rumored Takeover

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Harrow Health (HROW – Research Report), Accolade (AC...

Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW), Accolade (ACCD) and Champions Oncology (CSBR)

In a report released today, Gil Luria from D.A. Davidson maintained a Hold rating on Accolade (ACCD – Research Report). The company's shares closed...

D.A. Davidson Sticks to Their Hold Rating for Accolade (ACCD)

ABNB

AMCX

AMGN

ANET

APTV

CCOI

CELH

CHKP

CLOV

COST

CPNG

CPRI

CRWD

CSBR

DAVE

DDOG

ENVA

EXPE

FIVE

FSLY

FTNT

FWRD

GILD

GOOG

HESM

HROW

HTLF

INFN

ISPO

LIDR

LUMN

MNST

MSTR

NVST

PARAA

PLUG

SHOP

SILK

SKYW

SMCI

THRM

TTWO

UBER

UMBF

VZIO

WKME

WULF

Penny Stocks

Small Cap

Press Releases

ACCD Investors Have the Opportunity to Join Accolade, Inc. Securities Fraud Investigation with The Schall Law Firm

Legal

Accolade, Inc. (ACCD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accolade To Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

First-of-its-kind Healthcare Innovation Provides Synchronized, Customized Whole-Health Strategies

Accolade To Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Accolade to Announce Fiscal Second Quarter 2025 Financial Results

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

Biodesix

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Concord Medical Services

Cross Country Healthcare, Inc. - Common Stock

Cross Country Healthcare

Castle Biosciences

DocGo

Enhabit

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Euda Health Holdings Limited - Ordinary Shares

EUDA Health Holdings

Fulgent Genetics

InnovAge Holding

Pediatrix Medical Group, Inc. Common Stock

Pediatrix Medical Group

23andMe Holding

ModivCare

National Research Corporation - Common Stock

National Research

Nutex Health

Performant Financial Corporation - Common Stock

Performant Finl

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Accolade

Accolade (ACCD) Forecast

Accolade (NASDAQ:ACCD) Stock, Quote.Headers.trade-ideas